Quadrant Capital Group LLC Bei Gene, Ltd. Transaction History

Quadrant Capital Group LLC

$1.42 Billion
Q3 2024

A detailed history of Quadrant Capital Group LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 142 shares of BGNE stock, worth $27,447. This represents 0.0% of its overall portfolio holdings.

Number of Shares

142

Previous 63 125.4%

Holding current value

$27,447

Previous $8,000 287.5%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$143.93 - $224.51 $11,370 - $17,736	79 Added 125.4%	142 $31,000
Q2 2024 Aug 12, 2024	SELL	$129.52 - $174.32 $2,978 - $4,009	-23 Reduced 26.74%	63 $8,000
Q1 2024 May 15, 2024	SELL	$141.8 - $181.47 $3,970 - $5,081	-28 Reduced 24.56%	86 $13,000
Q4 2023 Feb 08, 2024	SELL	$158.67 - $201.58 $158 - $201	-1 Reduced 0.87%	114 $20,000
Q3 2023 Nov 14, 2023	BUY	$179.87 - $225.13 $539 - $675	3 Added 2.68%	115 $20,000
Q2 2023 Aug 09, 2023	SELL	$178.3 - $266.78 $356 - $533	-2 Reduced 1.75%	112 $19,000
Q1 2023 May 11, 2023	BUY	$215.53 - $274.5 $862 - $1,098	4 Added 3.64%	114 $24,000
Q4 2022 Feb 10, 2023	BUY	$125.51 - $229.3 $7,907 - $14,445	63 Added 134.04%	110 $24,000
Q3 2022 Nov 10, 2022	BUY	$131.8 - $202.24 $3,426 - $5,258	26 Added 123.81%	47 $6,000
Q2 2022 Aug 09, 2022	SELL	$121.11 - $216.05 $1,937 - $3,456	-16 Reduced 43.24%	21 $3,000
Q1 2022 May 06, 2022	SELL	$146.52 - $269.56 $37,802 - $69,546	-258 Reduced 87.46%	37 $7,000
Q4 2021 Feb 01, 2022	SELL	$248.56 - $389.34 $4,722 - $7,397	-19 Reduced 6.05%	295 $80,000
Q3 2021 Nov 12, 2021	BUY	$249.6 - $403.14 $21,964 - $35,476	88 Added 38.94%	314 $114,000
Q2 2021 Aug 09, 2021	BUY	$292.75 - $367.01 $12,002 - $15,047	41 Added 22.16%	226 $78,000
Q1 2021 May 12, 2021	SELL	$260.64 - $382.12 $14,335 - $21,016	-55 Reduced 22.92%	185 $64,000
Q4 2020 Feb 16, 2021	SELL	$221.31 - $316.61 $15,049 - $21,529	-68 Reduced 22.08%	240 $62,000
Q3 2020 Nov 13, 2020	BUY	$189.18 - $286.44 $25,728 - $38,955	136 Added 79.07%	308 $88,000
Q2 2020 Aug 13, 2020	SELL	$123.9 - $195.41 $117,952 - $186,030	-952 Reduced 84.7%	172 $32,000
Q1 2020 May 15, 2020	BUY	$121.84 - $173.19 $117,088 - $166,435	961 Added 589.57%	1,124 $139,000
Q4 2019 Feb 03, 2020	SELL	$115.78 - $208.34 $21,419 - $38,542	-185 Reduced 53.16%	163 $25,000
Q3 2019 Oct 24, 2019	SELL	$120.61 - $148.29 $17,729 - $21,798	-147 Reduced 29.7%	348 $42,000
Q2 2019 Jul 24, 2019	BUY	$113.99 - $146.86 $14,932 - $19,238	131 Added 35.99%	495 $60,000
Q1 2019 Apr 29, 2019	BUY	$122.82 - $151.83 $25,423 - $31,428	207 Added 131.85%	364 $47,000
Q4 2018 Jan 17, 2019	BUY	$107.01 - $175.15 $16,800 - $27,498	157 New	157 $22,000

Others Institutions Holding BGNE

# of Institutions

244

Shares Held

45.3M

Call Options Held

258K

Put Options Held

52.2K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $20B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.

Account

Quadrant Capital Group LLC Bei Gene, Ltd. Transaction History